Kodiak Sciences Inc. , today announced that it has completed enrollment in its GLOW2 Phase 3 clinical trial of tarcocimab tedromer in patients with diabetic retinopathy ("DR"). "We randomized more ...

New anti–vascular endothelial growth factor (VEGF) therapies are improving retinal disease management by providing patients ...

According to Future Market Insight, the global diabetic retinopathy market is likely to reach USD 15.50 billion by 2033, registering a CAGR of 5.8%. This is a significant rise from the estimated value ...

Cataract surgery was associated with an increased risk of worsening diabetic retinopathy in adults with type 2 diabetes, according to a retrospective analysis. After propensity score matching, ...

If blood sugar goes uncontrolled, diabetes causes progressive damage to structures in the eyes. The ongoing eye damage leads to diabetic eye diseases like retinopathy, cataracts, and glaucoma. People ...

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

Retinal Biologics MarketThe Retinal Biologics Market generated USD 19.96 billion in revenue in 2021 and is projected to grow to USD 41.92 billion by 2028, expanding at a CAGR of 11.1% from 2022 to ...